Open AccessDiffuse erythematous rash after teneligliptin therapy: A case report
Author(s) -
Prabhat Agrawal,
Apoorv Jain,
Saurabh Bansal,
Abhishek Raj
Publication year - 2018
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_283_18
Subject(s) - medicine , rash , discontinuation , dermatology , adverse effect , dipeptidyl peptidase 4 inhibitor , drug , lesion , surgery , pharmacology , diabetes mellitus , type 2 diabetes , endocrinology
We report a yet unreported, adverse effect of teneligliptin [Dipeptidyl peptidase IV inhibitor (DPP IV)] presenting as diffuse pruritic erythematous rash, in a patient, 2 days after initiation of the drug. The rash waned off after the discontinuation of the drug without any residual lesion.